North Carolina is currently home to 2641 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
NCT06843590
Recruiting
The purpose of this study is to measure the safety and decrease in daytime sleepiness in subjects with Idiopathic Hypersomnia when taking ALKS 2680 tablets compared with placebo tablets
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/27/2025
Locations: Alkermes Investigational Site, Denver, North Carolina
Conditions: Idiopathic Hypersomnia
Register for Updates
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
NCT06712823
Recruiting
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).
Gender:
ALL
Ages:
16 years and above
Trial Updated:
06/27/2025
Locations: Crinetics Study Site, Morehead City, North Carolina
Conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Register for Updates
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
NCT06555783
Recruiting
The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/27/2025
Locations: Alkermes Investigator Site, Denver, North Carolina
Conditions: Narcolepsy Type 2
Register for Updates
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06223516
Recruiting
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety and pharmacokinetics of ABBV-383 in adult participants with relapsed/refractory (R/R) MM. ABBV-383 is an i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Atrium Health Wake Forest Baptist Medical Center /ID# 260807, Winston-Salem, North Carolina
Conditions: Multiple Myeloma
Register for Updates
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPĪ±-CD47 Pathway, in Solid or Hematological Tumors
NCT05892718
Recruiting
The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Carolina BioOncology, Huntersville, North Carolina
Conditions: Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma
Register for Updates
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
NCT05776225
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/27/2025
Locations: Onsite Clinical Solutions, LLC, Charlotte, North Carolina
Conditions: Primary Generalized Tonic-Clonic Seizures
Register for Updates
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
NCT05614063
Recruiting
The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Onsite Clinical Solutions, LLC, Charlotte, North Carolina
Conditions: Focal Onset Seizures
Register for Updates
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
NCT05575492
Recruiting
The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive female and male participants 9 to 15 years of age. In addition, mRNA-1647 will be evaluated in female participants 16 to 25 years as a comparator cohort.
Gender:
ALL
Ages:
Between 9 years and 25 years
Trial Updated:
06/27/2025
Locations: OnSite Clinical Solutions, LLC - ClinEdge - PPDS, Charlotte, North Carolina
Conditions: Cytomegalovirus
Register for Updates
Conversations You Want About Corona Virus Disease (COVID-19)
NCT05191420
Recruiting
Web-enabled virtual topical guide: develop virtual conversations for each concern and intensity level
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Wake Forest Health Sciences, Winston-Salem, North Carolina
Conditions: Covid19
Register for Updates
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
NCT05066217
Recruiting
This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole HCL (EPX-100) as adjunctive therapy in children and adult participants with Lennox-Gastaut syndrome (LGS).
Gender:
ALL
Ages:
Between 2 years and 55 years
Trial Updated:
06/27/2025
Locations: On-Site Clinical Solution, Raleigh, North Carolina
Conditions: Lennox Gastaut Syndrome
Register for Updates
Women s Health Awareness Community Resiliency, Environmental Action and Collaborations for Health (REACH) Equity
NCT04983251
Recruiting
Background: Inequalities in COVID-19 infection, hospitalization, and death in under-studied, under-represented, and under-reported groups of people are severe. A growing number of studies have assessed the impact of individual risk factors. But few studies have assessed which factors are the greatest drivers of COVID-19 disparities from a wider perspective. Objective: To understand the long-term impacts of COVID-19 on minority women and their families to assist in developing community-based p... Read More
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
06/27/2025
Locations: NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina
Conditions: Mental Health
Register for Updates